Toward predictors of survival in castration-resistant prostate cancer

Julie N. Graff, Tomasz M. Beer

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

Original languageEnglish (US)
Pages (from-to)3882-3884
Number of pages3
Issue number17
StatePublished - Sep 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Toward predictors of survival in castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this